Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2025 Filed Aug 19, 2025 21:29 UTC |
Herr Amy E.Director
|
Exercise / conversionCommon Stock | 279 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014701 · form4.xml · nonDerivative · entry 2 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 2,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
Kelderman KimDirector · Chief Executive Officer
|
GrantStock Options (Right to Buy) · Derivative | 90,441 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001062993-25-014700 · form4.xml · derivative · entry 19 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,441 Underlying: Common Stock · 90,441 shares Expires 2035-08-15 F12 · derivative.exercise_date: Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
Kelderman KimDirector · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 35,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014700 · form4.xml · derivative · entry 18 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,354 Underlying: Common Stock · 35,354 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028. F11 · derivative.expiration_date: 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
Kelderman KimDirector · Chief Executive Officer
|
GrantPerformance Restricted Stock Units · Derivative | 70,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014700 · form4.xml · derivative · entry 17 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,708 Underlying: Common Stock · 70,708 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F10 · derivative.expiration_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 8,543 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014700 · form4.xml · derivative · entry 15 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,087 Underlying: Common Stock · 8,543 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8 · derivative.exercise_date: 8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. F8 · derivative.expiration_date: 8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 4,305 | $53.60 | $230,748.00 |
DisclosureSEC source: 0001062993-25-014700 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,968 Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 8,543 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014700 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:27 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantStock Options (Right to Buy) · Derivative | 24,758 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001062993-25-014697 · form4.xml · derivative · entry 14 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,758 Underlying: Common Stock · 24,758 shares Expires 2035-08-15 F12 · derivative.exercise_date: Options to purchase 8,253 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,252 shares vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:27 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantRestricted Stock Units · Derivative | 9,678 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014697 · form4.xml · derivative · entry 13 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,678 Underlying: Common Stock · 9,678 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 3,226 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. F11 · derivative.expiration_date: 3,226 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:27 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantPerformance Restricted Stock Units · Derivative | 19,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014697 · form4.xml · derivative · entry 12 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,355 Underlying: Common Stock · 19,355 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F10 · derivative.expiration_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:27 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Exercise / conversionRestricted Stock Units · Derivative | 2,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014697 · form4.xml · derivative · entry 10 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,246 Underlying: Common Stock · 2,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8 · derivative.exercise_date: 2,623 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027. F8 · derivative.expiration_date: 2,623 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:27 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Tax withholdingCommon Stock | 803 | $53.60 | $43,040.80 |
DisclosureSEC source: 0001062993-25-014697 · form4.xml · nonDerivative · entry 2 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,112 Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:27 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Exercise / conversionCommon Stock | 2,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014697 · form4.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
Bohnen ShaneSVP - General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 17,897 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001062993-25-014699 · form4.xml · derivative · entry 18 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,897 Underlying: Common Stock · 17,897 shares Expires 2035-08-15 F14 · derivative.exercise_date: Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
Bohnen ShaneSVP - General Counsel
|
GrantRestricted Stock Units · Derivative | 6,996 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014699 · form4.xml · derivative · entry 17 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,996 Underlying: Common Stock · 6,996 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F13 · derivative.exercise_date: 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. F13 · derivative.expiration_date: 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
Bohnen ShaneSVP - General Counsel
|
GrantPerformance Restricted Stock Units · Derivative | 13,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014699 · form4.xml · derivative · entry 16 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,992 Underlying: Common Stock · 13,992 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12 · derivative.exercise_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F12 · derivative.expiration_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
Bohnen ShaneSVP - General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 1,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014699 · form4.xml · derivative · entry 14 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,338 Underlying: Common Stock · 1,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027. F10 · derivative.expiration_date: 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
Bohnen ShaneSVP - General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 50 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014699 · form4.xml · derivative · entry 10 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49 Underlying: Common Stock · 50 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7 · derivative.exercise_date: 49 restricted stock units vest on 8/15/2026. F7 · derivative.expiration_date: 49 restricted stock units vest on 8/15/2026. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
Bohnen ShaneSVP - General Counsel
|
Tax withholdingCommon Stock | 527 | $53.60 | $28,247.20 |
DisclosureSEC source: 0001062993-25-014699 · form4.xml · nonDerivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,385 Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
Bohnen ShaneSVP - General Counsel
|
Exercise / conversionCommon Stock | 1,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014699 · form4.xml · nonDerivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
McManus MatthewPresident - Diag & Spatial Bio
|
GrantStock Option (Right to Buy) · Derivative | 24,614 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001062993-25-014698 · form4.xml · derivative · entry 12 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,614 Underlying: Common Stock · 24,614 shares Expires 2035-08-15 F10 · derivative.exercise_date: Options to purchase 8,205 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,204 shares vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
McManus MatthewPresident - Diag & Spatial Bio
|
GrantRestricted Stock Units · Derivative | 9,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014698 · form4.xml · derivative · entry 11 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,622 Underlying: Common Stock · 9,622 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: 3,207 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 3,208 restricted stock units vest on 8/15/2028. F9 · derivative.expiration_date: 3,207 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 3,208 restricted stock units vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
McManus MatthewPresident - Diag & Spatial Bio
|
GrantPerformance Restricted Stock Units · Derivative | 19,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014698 · form4.xml · derivative · entry 10 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,243 Underlying: Common Stock · 19,243 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8 · derivative.exercise_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F8 · derivative.expiration_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
McManus MatthewPresident - Diag & Spatial Bio
|
Exercise / conversionRestricted Stock Units · Derivative | 2,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014698 · form4.xml · derivative · entry 8 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,275 Underlying: Common Stock · 2,637 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6 · derivative.exercise_date: 2,637 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 2,638 restricted stock units vest on 8/15/2027. F6 · derivative.expiration_date: 2,637 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 2,638 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
McManus MatthewPresident - Diag & Spatial Bio
|
Tax withholdingCommon Stock | 880 | $53.60 | $47,168.00 |
DisclosureSEC source: 0001062993-25-014698 · form4.xml · nonDerivative · entry 2 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,735 Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC |
McManus MatthewPresident - Diag & Spatial Bio
|
Exercise / conversionCommon Stock | 2,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014698 · form4.xml · nonDerivative · entry 1 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 23:06 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,040 | $0.00 Strike: $21.84 | $0.00 |
DisclosureSEC source: 0001437749-25-026007 · rdgdoc.xml · derivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,040 shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 23:06 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionCommon Stock | 5,040 | $21.84 | $110,073.60 |
DisclosureSEC source: 0001437749-25-026007 · rdgdoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 20:28 UTC |
Hippel JamesCFO
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 168,620 | $0.00 Strike: $44.33 | $0.00 |
DisclosureSEC source: 0001062993-25-013359 · form4.xml · derivative · entry 3 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 168,620 shares Expires 2025-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 20:28 UTC |
Hippel JamesCFO
|
Tax withholdingCommon Stock | 147,431 | $58.55 | $8,632,085.05 |
DisclosureSEC source: 0001062993-25-013359 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,799 Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 20:28 UTC |
Hippel JamesCFO
|
Exercise / conversionCommon Stock | 168,620 | $44.33 | $7,474,924.60 |
DisclosureSEC source: 0001062993-25-013359 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 20:26 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 48,176 | $0.00 Strike: $44.33 | $0.00 |
DisclosureSEC source: 0001062993-25-013134 · form4.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,176 shares Expires 2025-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 20:26 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 43,649 | $53.12 | $2,318,634.88 |
DisclosureSEC source: 0001062993-25-013134 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,730 Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 20:26 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 48,176 | $44.33 | $2,135,642.08 |
DisclosureSEC source: 0001062993-25-013134 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:04 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 36,132 | $0.00 Strike: $44.33 | $0.00 |
DisclosureSEC source: 0001062993-25-012967 · form4.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,176 Underlying: Common Stock · 36,132 shares Expires 2025-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:04 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 32,933 | $51.42 | $1,693,414.86 |
DisclosureSEC source: 0001062993-25-012967 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,203 Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:04 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 36,132 | $44.33 | $1,601,731.56 |
DisclosureSEC source: 0001062993-25-012967 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:20 UTC |
Herr Amy E.Director
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,280 | $0.00 Strike: $44.33 | $0.00 |
DisclosureSEC source: 0001062993-25-011400 · form4.xml · derivative · entry 5 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 0 Underlying: Common Stock · 1,280 shares Expires 2025-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:20 UTC |
Herr Amy E.Director
|
SaleCommon Stock | 1,280 | $49.77 | $63,704.83 |
DisclosureSEC source: 0001062993-25-011400 · form4.xml · nonDerivative · entry 3 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 1,976 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 49.7471 to 49.8100, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:20 UTC |
Herr Amy E.Director
|
Exercise / conversionCommon Stock | 1,280 | $44.33 | $56,742.40 |
DisclosureSEC source: 0001062993-25-011400 · form4.xml · nonDerivative · entry 2 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 3,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:18 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $21.84 | $0.00 |
DisclosureSEC source: 0001062993-25-008474 · form4.xml · derivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,040 Underlying: Common Stock · 12,000 shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:18 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionCommon Stock | 12,000 | $21.84 | $262,080.00 |
DisclosureSEC source: 0001062993-25-008474 · form4.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 20:25 UTC |
Bohnen ShaneSVP - General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 2,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-007136 · form4.xml · derivative · entry 8 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,259 Underlying: Common Stock · 2,260 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6 · derivative.exercise_date: 2,259 restricted stock units vest on 4/3/2026. F6 · derivative.expiration_date: 2,259 restricted stock units vest on 4/3/2026. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 20:25 UTC |
Bohnen ShaneSVP - General Counsel
|
Tax withholdingCommon Stock | 747 | $54.86 | $40,980.42 |
DisclosureSEC source: 0001062993-25-007136 · form4.xml · nonDerivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,194 Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 20:25 UTC |
Bohnen ShaneSVP - General Counsel
|
Exercise / conversionCommon Stock | 2,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-007136 · form4.xml · nonDerivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC |
Herr Amy E.Director
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,976 | $0.00 Strike: $44.33 | $0.00 |
DisclosureSEC source: 0001062993-25-002706 · form4.xml · derivative · entry 5 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 1,280 Underlying: Common Stock · 3,256 shares Expires 2025-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC |
Herr Amy E.Director
|
SaleCommon Stock | 1,860 | $65.96 | $122,690.62 |
DisclosureSEC source: 0001062993-25-002706 · form4.xml · nonDerivative · entry 3 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 1,976 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC |
Herr Amy E.Director
|
Exercise / conversionCommon Stock | 1,976 | $44.33 | $87,596.08 |
DisclosureSEC source: 0001062993-25-002706 · form4.xml · nonDerivative · entry 2 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 3,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2025 Filed Feb 7, 2025 21:56 UTC |
Herr Amy E.Director
|
GrantRestricted Stock Units · Derivative | 115 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001897 · form4.xml · derivative · entry 14 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 115 Underlying: Common Stock · 115 shares Expires not disclosed F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028. F11 · derivative.expiration_date: 38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028. Read SEC document |
| February 03, 2025 Filed Feb 7, 2025 21:56 UTC |
Herr Amy E.Director
|
GrantStock Option (Right to Buy) · Derivative | 344 | $0.00 Strike: $72.05 | $0.00 |
DisclosureSEC source: 0001062993-25-001897 · form4.xml · derivative · entry 11 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 344 Underlying: Common Stock · 344 shares Expires 2025-02-03 F7 · derivative.exercise_date: 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.